Close Menu
  • Home
  • Technology
  • Devices
  • Business
  • Science
  • Gadgets
  • Startups
Ayaksız
  • Home
  • Technology

    Lucid and Bolt Plan 25,000 Robotaxis for Europe

    Eylül 18, 2026

    AMD Gives PC Builders More Choice With New Ryzen 5 Desktop Chips

    Eylül 11, 2026

    Apple Expands Device Protection With a $49.99 Family Plan

    Eylül 11, 2026

    Snapdragon 8 Elite Extreme Gen 6 Reportedly Beats MediaTek’s Next Flagship Chipset

    Eylül 11, 2026

    Pinterest CFO Julia Donnelly to Step Down in October

    Ağustos 30, 2026
  • Devices

    Projector Setup: Separate Placement, Lens Shift, Zoom, and Keystone

    Kasım 18, 2026

    Router Mode or Access Point Mode? Give Each Network Device a Clear Job

    Kasım 18, 2026

    Scanner Feeder or Glass? Choose According to the Original

    Kasım 13, 2026

    Borderless Printing: Why the Edges of Your Photo Can Disappear

    Kasım 12, 2026

    Camera AE Lock: Recompose a Scene Without Letting Exposure Drift

    Kasım 11, 2026
  • Business

    Google Pixel 11 Pro Leaked Renders Indicate It Might Sport Thinner Bezels Than the Pixel 10 Pro

    Mart 30, 2026

    Motorola Edge 70 Debuts With Snapdragon 7 Gen 4, Ultra-Slim 5.99mm Body

    Kasım 5, 2025

    Samsung Galaxy S26 Series Could See Price Increase Amid Rising Component Costs: Report

    Kasım 4, 2025

    Amazon’s AWS Partners with NBA to Power New AI Basketball Platform

    Ekim 4, 2025

    Billionaire-Backed Bitcoin Firm OranjeBTC to List on Brazil’s B3 Exchange

    Ekim 4, 2025
  • Science

    Double Rainbows: Why the Outer Arc Reverses Its Colors

    Kasım 18, 2026

    Why Ice Floats—and Why Water Behaves Differently Near Freezing

    Kasım 13, 2026

    Air Pressure and Altitude: Why Two Weather Readings May Not Be Comparable

    Kasım 12, 2026

    A Light-Year Measures Distance: Understanding the Scale Behind Space Headlines

    Kasım 11, 2026

    Why the Sky Is Blue—and Why the Same Atmosphere Produces Red Sunsets

    Kasım 10, 2026
  • Gadgets

    Tripod Center Columns: Extra Height Comes with a Stability Tradeoff

    Kasım 18, 2026

    E Ink Ghosting: Match the Refresh Mode to the Task

    Kasım 13, 2026

    Camera Lens Hoods: Choose the Right Shape and Check the Whole Frame

    Kasım 12, 2026

    Pop Filters and Windscreens: Match Microphone Protection to the Noise

    Kasım 12, 2026

    USB Hub Power: Check Where Your Connected Devices Get Their Energy

    Kasım 11, 2026
  • Startups

    Cache-Control for Startups: No-Cache and No-Store Solve Different Problems

    Kasım 18, 2026

    Dead-Letter Queues: Investigate Before Replaying Failed Messages

    Kasım 13, 2026

    Database Connection Pools: Budget Across Every Application Replica

    Kasım 13, 2026

    Startup Staging Sites: Separate Search Visibility from Access Control

    Kasım 12, 2026

    API Idempotency Keys: Keep a Retry Connected to the Original Operation

    Kasım 11, 2026
Ayaksız
Anasayfa » Blog » Novo Nordisk Expands AI Partnership with Valo Health for Obesity Drug Development
Tech

Novo Nordisk Expands AI Partnership with Valo Health for Obesity Drug Development

By ayaksızOcak 18, 2025Yorum yapılmamış2 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

Novo Nordisk, the Danish pharmaceutical giant, has announced an expansion of its partnership with U.S.-based tech firm Valo Health to develop new treatments for cardiometabolic diseases, including obesity, using human data and artificial intelligence (AI).

The expanded collaboration follows a recent setback for Novo, as its weight-loss drug candidate CagriSema underperformed in trials, falling short of expectations. This comes as Novo seeks to develop a more potent weight-loss treatment to rival Eli Lilly’s Zepbound, a competitor in the obesity drug market. Both companies are also exploring the broader health benefits of their obesity treatments, as they look to expand their utility beyond weight loss. Analysts predict the obesity drug market could be worth $150 billion within the next decade.

Originally announced in September 2023, the partnership between Novo and Valo aimed to develop up to 11 drugs. With the new agreement, the scope has broadened, with plans to discover and develop up to 20 new treatments for obesity, type 2 diabetes, and cardiovascular diseases.

Under the terms of the expanded deal, Valo Health stands to receive up to $190 million in near-term payments, along with potential milestone payments totaling about $4.6 billion. The original agreement entitled Valo to up to $2.7 billion in milestone payments.

 

AI CagriSema cardiometabolic diseases milestone payments Novo Nordisk obesity drugs partnership type 2 diabetes Valo Health Weight Loss Zepbound
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
ayaksız
  • Website

Related Posts

Lucid and Bolt Plan 25,000 Robotaxis for Europe

Eylül 18, 2026

AMD Gives PC Builders More Choice With New Ryzen 5 Desktop Chips

Eylül 11, 2026

Apple Expands Device Protection With a $49.99 Family Plan

Eylül 11, 2026
Add A Comment

Comments are closed.

Recent Posts
  • Projector Setup: Separate Placement, Lens Shift, Zoom, and Keystone
  • Cache-Control for Startups: No-Cache and No-Store Solve Different Problems
  • Tripod Center Columns: Extra Height Comes with a Stability Tradeoff
  • Double Rainbows: Why the Outer Arc Reverses Its Colors
  • Router Mode or Access Point Mode? Give Each Network Device a Clear Job
Tags
AI AI Chips AI Infrastructure Amazon Android Apple Artificial Intelligence Bitcoin ChatGPT China Cryptocurrency Cybersecurity data centers DeepSeek Donald Trump Electric Vehicles Elon Musk Ether Generative AI Google Huawei India Investment Iphone Meta Microsoft NASA National Security Nvidia OnePlus OpenAI Oppo Realme Samsung semiconductor industry Social media Sony SpaceX Technology Tesla Tether TikTok Vivo WhatsApp Xiaomi
Ayaksız
Instagram
© 2026 Ayaksız.

Type above and press Enter to search. Press Esc to cancel.